Correlation of baseline PsA-modified vdH-S scores with baseline PsA parameters
PsA, Psoriasis, der Heijde-Sharp, psoriasis, PsO
PSORIATIC ARTHRITIS, PSORIASIS, PSORIASIS
Among all patients in the combined guselkumab group, PsA and PsO duration, CRP level, age, and SJC at baseline were weakly correlated with baseline PsA-modified vdH-S total score. No correlation was observed between baseline PASI and vdH-S scores (Table Correlation between baseline total PsA-modified vdH-S score and known baseline risk factors of radiographic progression among patients randomized to receive guselkumab Q4W or Q8W (CRP = C-reactive protein; PASI = Psoriasis Area and Severity Index; PsA = psoriatic arthritis; PsO = psoriasis; Q4W = every 4 weeks; Q8W = every 8 weeks; SJC = swollen joint count; vdH-S = van der Heijde-Sharp